Literature DB >> 16273093

A quantitative protein interaction network for the ErbB receptors using protein microarrays.

Richard B Jones1, Andrew Gordus, Jordan A Krall, Gavin MacBeath.   

Abstract

Although epidermal growth factor receptor (EGFR; also called ErbB1) and its relatives initiate one of the most well-studied signalling networks, there is not yet a genome-wide view of even the earliest step in this pathway: recruitment of proteins to the activated receptors. Here we use protein microarrays comprising virtually every Src homology 2 (SH2) and phosphotyrosine binding (PTB) domain encoded in the human genome to measure the equilibrium dissociation constant of each domain for 61 peptides representing physiological sites of tyrosine phosphorylation on the four ErbB receptors. This involved 77,592 independent biochemical measurements and provided a quantitative protein interaction network that reveals many new interactions, including ones that fall outside of our current view of domain selectivity. By slicing through the network at different affinity thresholds, we found surprising differences between the receptors. Most notably, EGFR and ErbB2 become markedly more promiscuous as the threshold is lowered, whereas ErbB3 does not. Because EGFR and ErbB2 are overexpressed in many human cancers, our results suggest that the extent to which promiscuity changes with protein concentration may contribute to the oncogenic potential of receptor tyrosine kinases, and perhaps other signalling proteins as well.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273093     DOI: 10.1038/nature04177

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  273 in total

Review 1.  A vision for a biomedical cloud.

Authors:  R L Grossman; K P White
Journal:  J Intern Med       Date:  2012-02       Impact factor: 8.989

2.  Simultaneous measurement of 10,000 protein-ligand affinity constants using microarray-based kinetic constant assays.

Authors:  James P Landry; Yiyan Fei; Xiangdong Zhu
Journal:  Assay Drug Dev Technol       Date:  2011-12-22       Impact factor: 1.738

3.  Analyzing the homeostasis of signaling proteins by a combination of Western blot and fluorescence correlation spectroscopy.

Authors:  Yi-Da Chung; Michael D Sinzinger; Petra Bovee-Geurts; Marina Krause; Sip Dinkla; Irma Joosten; Werner J Koopman; Merel J W Adjobo-Hermans; Roland Brock
Journal:  Biophys J       Date:  2011-12-07       Impact factor: 4.033

4.  Sequential multiplex analyte capturing for phosphoprotein profiling.

Authors:  Oliver Poetz; Tanja Henzler; Michael Hartmann; Cornelia Kazmaier; Markus F Templin; Thomas Herget; Thomas O Joos
Journal:  Mol Cell Proteomics       Date:  2010-08-03       Impact factor: 5.911

Review 5.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.

Authors:  Walter Kolch; Andrew Pitt
Journal:  Nat Rev Cancer       Date:  2010-08-19       Impact factor: 60.716

6.  ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.

Authors:  J Spencer Liles; Juan Pablo Arnoletti; Ching-Wei D Tzeng; J Harrison Howard; Andrew V Kossenkov; Peter Kulesza; Martin J Heslin; Andrey Frolov
Journal:  Cancer Biol Ther       Date:  2010-09-30       Impact factor: 4.742

Review 7.  The discovery of modular binding domains: building blocks of cell signalling.

Authors:  Bruce J Mayer
Journal:  Nat Rev Mol Cell Biol       Date:  2015-09-30       Impact factor: 94.444

Review 8.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

9.  ERBB2 signaling drives supporting cell proliferation in vitro and apparent supernumerary hair cell formation in vivo in the neonatal mouse cochlea.

Authors:  Jingyuan Zhang; Quan Wang; Dunia Abdul-Aziz; Jonelle Mattiacio; Albert S B Edge; Patricia M White
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

Review 10.  The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

Authors:  Natalia V Sergina; Mark M Moasser
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.